Clinical Trial Update: Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years

View source ↗

Summary

A completed trial comparing Flublok recombinant influenza vaccine with a standard-dose influenza vaccine in adults aged 18-64, with results posted in April 2025…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Lower Respiratory Tract Infection
• Myocardial Infarction
• Pneumonia
• Stroke

Drugs mentioned

• Flublok (influenza vaccine, recombinant)

Snippet

Sponsor: Kaiser Permanente | Conditions: Influenza, Pneumonia | Status: COMPLETED | Results posted: 2025-04-08